Compare GeneDx Holdings Corp (WGS) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Exxon Mobil Corporation — how do they compare? GeneDx Holdings Corp trades at $67.74 (market cap $2.02B), while Exxon Mobil Corporation trades at $169.14 (market cap $692.86B). The key difference: Exxon Mobil Corporation is far larger — about 343× GeneDx Holdings Corp's market cap, and Exxon Mobil Corporation pays a 2.45% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Exxon Mobil Corporation for 99 Days on average.
| WGS | XOM | |
|---|---|---|
Market Cap | $2.02B | $692.86B |
Volume | 734,640 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $167.51 | $171.52 |
52-Week Low | $34.51 | $110.64 |
Typical Hold Time | 19 Days | 99 Days |
Enterprise Value | $2.05B | $724.64B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Exxon Mobil (XOM) trades at $164.06, down 0.26% on the day, with a bullish technical signal and strong support at $163. The company reported mixed Q2 2026 earnings, missing EPS estimates, but maintains solid profitability with a 9.07% net margin. Recent news highlights potential expansion into Venezuela's oil fields and ongoing growth in Guyana and Permian Basin assets. Cash flow from operations remains robust at $52.0 billion in 2025, though net cash flow was negative due to high capital expenditures.
XOM offers a stable dividend and growth potential from strategic investments, but faces risks from volatile oil prices and geopolitical exposure. Analyst consensus is a 'Hold' with a $169.45 price target, indicating modest upside. Revenue declines from 2022-2025 pose a concern, but projected 2026 growth to $361.1 billion may reverse the trend. The stock's valuation ratios, including a P/E of 21.69, are reasonable for the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
